MarketPulse

glycemic control

2 articles
BenzingaBenzinga··Vandana Singh

Novo Nordisk's Experimental Obesity Drug Shows Superior Results to Semaglutide

Novo Nordisk and United Biotechnology's experimental drug UBT251 outperformed semaglutide in phase 2 trials, delivering stronger weight loss and glucose control.
LLYNVOweight losssemaglutide
GlobeNewswire Inc.GlobeNewswire Inc.··Senseonics Holdings, Inc.

Senseonics' Eversense 365 Proves Durable: Real-World Data Shows 94% Wear Rate, Strong Glucose Control

Senseonics reports real-world data from 5,059 Eversense 365 CGM users showing 93.8% wear time and strong glucose control metrics over one year.
SENSmedical devicediabetes management